Successful Mobilization, Intra-Apheresis Recruitment, and Harvest of Hematopoietic Progenitor Cells by Addition of Plerixafor and Subsequent Large-Volume Leukapheresis

Andreas Humpe  Ute Buwitt-Beckmann  Natalie Schub  Martin Gramatzki  Andreas Günther
Division of Stem Cell Transplantation and Immunotherapy, Second Department of Medicine, University Hospital Schleswig-Holstein, Campus Kiel, Germany

Keywords
Plerixafor · HPC products · Large-volume leukapheresis · Poor or non-optimal mobiliser

Summary
Background: In patients failing successful conventional mobilization of hematopoietic progenitor cells (HPC) plerixafor (Mozobil®) seems to be an alternative. We report a series of 14 patients with multiple myeloma or NHL successfully mobilized and harvested by plerixafor together with large-volume leukaphereses (LVL). Methods: In a first series (GI), 5 patients were mobilized with G-CSF and plerixafor. In the second series (GII), 9 patients were mobilized by chemotherapy, G-CSF, and plerixafor. Results: In GI and GII, addition of plerixafor led to a significant (p < 0.01) increase of leukocytes and CD34+ cells in peripheral blood (PB). In GII, the median number of CD34+ cells in PB before and after addition of plerixafor was significantly (p = 0.019) higher compared to GI (9 vs. 5 and 50 vs. 24 cells/μl, respectively). In GI and GII, a median number of three or one aphereses was performed. In GII, the median yield (6.7 × 10⁶ CD34+ cells/kg) of the first apheresis and the median intra-apheresis recruitment of CD34+ cells were significantly (p < 0.05) higher compared to GI (2.94 × 10⁶ CD34+ cells/kg). All patients transplanted, 5 in GI and 8 in GII, exhibited successful engraftment. Conclusions: Plerixafor and G-CSF mobilization or the addition of plerixafor during non-optimal chemotherapy and G-CSF mobilization together with LVL enabled, independent of leukocyte count and even without detectable CD34+ cells before addition of plerixafor, sufficient harvest of HPC numbers for transplantation. Addition of plerixafor during chemotherapy and G-CSF mobilization led to an increased intra-apheresis recruitment and a significantly higher yield of CD34+ cells compared to plerixafor and G-CSF steady-state mobilized patients.

Introduction
Transplantation of hematopoietic progenitor cells (HPC) has become a widely accepted therapeutic option, particularly for patients with chemotherapy-sensitive hematological malignancies. Transplantation of HPC offers several advantages compared to bone marrow. Collection of HPC can be performed without general anesthesia, engraftment is faster, and supportive care and costs are reduced. HPC are harvested by leukapheresis after mobilization with chemotherapy and/or G-CSF [1, 2].

A decisive factor for patients being transplanted in an autologous setting is the dose of transplanted HPC usually determined by measurement of CD34+ cells. Some data suggest that transplantation with less than 2 million of CD34+ cells/kg body weight (bw) is associated with a prolonged hematologic engraftment and worse outcome, whereas a dose of more than 5 million CD34+ cells/kg bw was of benefit [3]. In addition several data suggest that a minimum of 1.5 million [4], 2.5 million, or more than 5 million CD34+ cells might result in better outcome because of more rapid hematological engraftment and a decrease in infectious episodes [5]. Some data even suggest that patients might benefit of a dose higher than 15 million
CD34+ cells/kg bw with regard to engraftment and hospitalization time after transplantation [6]. Therefore, 2–4 × 10⁶ CD34+ cells/kg bw were recently defined as minimum and 8–10 × 10⁶ CD34+ cells/kg bw as optimum dose for autologous (tandem) transplantation in patients with multiple myeloma (MM) [7].

To achieve a sufficient number of CD34+ cells for transplantation, it is necessary to optimally mobilize and harvest HPC. Several factors have been identified being associated with poor mobilization, e.g., number of previous chemotherapy cycles, chemotherapy with stem cell-toxic substances like fludarabine, melphalan or lenalidomide, previous radiotherapy, and disease status [3, 8–12]. Depending on diagnosis, different mobilization failure rates up to about 30% are reported in the literature [13]. Therefore, strategies to identify poor mobilizing patients upfront or alternatives to improve mobilization regimens in non-optimally mobilizing patients are needed. Recently published data [14] suggest that patients exhibiting a peak count of less than 20 CD34+ cells/µl could be considered poor mobilizer.

Plerixafor (Mozobil®, Genzyme GmbH, Neu-Isenburg, Germany) is such a new alternative. It is an inhibitor of the CXCR4 chemokine receptor and blocks binding of its cognate ligand stromal cell-derived factor-1 alpha (SDF-1α) [15, 16]. In two prospective, randomized, placebo-controlled phase III trials in patients with non-Hodgkin’s lymphoma (NHL) [17] or MM [18], it was shown that administration of plerixafor led to a significantly higher number of CD34+ cells/kg bw with less aphereses compared to those obtained in the G-CSF and placebo groups.

Additionally, not only the mobilization strategy but also the apheresis should be tailored to the patient’s needs. It was already shown that large-volume leukapheresis (LVL) may result in an intra-apheresis recruitment of CD34+ cells in the range of up to 3.5 × 10⁶ CD34+ cells/kg bw, therefore representing an additional tool for improving the yield in poor or non-optimally mobilizing patients [19–22].

We compared mobilization and apheresis data of two groups of patients undergoing mobilization with plerixafor. In the first group (GI), plerixafor was added during a steady-state mobilization with G-CSF after previous failure of HPC mobilization, whereas in the second group (GII) plerixafor was added during an ongoing chemotherapy and G-CSF mobilization on the basis of poor or non-optimal CD34+ cell counts in peripheral blood (PB) not allowing for harvest of sufficient numbers of CD34+ cells for transplantation in a single apheresis.

### Table 1. Summary of patient characteristics

<table>
<thead>
<tr>
<th>Patient number</th>
<th>Sex</th>
<th>Age, years</th>
<th>Diagnosis</th>
<th>Previous radiation</th>
<th>Previous cycles of chemotherapy</th>
<th>Number of aphereses</th>
<th>Times the processed total peripheral blood volume, a / b</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>m</td>
<td>52</td>
<td>MM</td>
<td>yes</td>
<td>3× VelCD, 1× Cy 2 g/m²</td>
<td>3</td>
<td>4.1 / 13.1</td>
</tr>
<tr>
<td>2</td>
<td>m</td>
<td>44</td>
<td>MM</td>
<td>none</td>
<td>1× VelCD, 2× VelCD,</td>
<td>2</td>
<td>3.4 / 7.1</td>
</tr>
<tr>
<td>3</td>
<td>f</td>
<td>45</td>
<td>NHL</td>
<td>none</td>
<td>1× Cy 3g/m², 1× Cy 2 g/m²</td>
<td>2</td>
<td>3.9 / 9.6</td>
</tr>
<tr>
<td>4</td>
<td>f</td>
<td>65</td>
<td>MM</td>
<td>none</td>
<td>5× R-CHOP, 6× R-FC,</td>
<td>2</td>
<td>5.6 / 18.2</td>
</tr>
<tr>
<td>5</td>
<td>m</td>
<td>58</td>
<td>MM</td>
<td>yes</td>
<td>3× VelCD, 1× Cy 3 g/m²</td>
<td>3</td>
<td>4.4 / 14.7</td>
</tr>
<tr>
<td>6</td>
<td>f</td>
<td>69</td>
<td>MM</td>
<td>yes</td>
<td>1× VMP, 3× VelCD</td>
<td>1</td>
<td>5.1 / –</td>
</tr>
<tr>
<td>7</td>
<td>m</td>
<td>61</td>
<td>NHL</td>
<td>yes</td>
<td>6× R-CHOP</td>
<td>1</td>
<td>3.6 / –</td>
</tr>
<tr>
<td>8</td>
<td>f</td>
<td>68</td>
<td>MM</td>
<td>none</td>
<td>none</td>
<td>1</td>
<td>5.8 / –</td>
</tr>
<tr>
<td>9</td>
<td>m</td>
<td>56</td>
<td>MM</td>
<td>none</td>
<td>3× VelCD</td>
<td>1</td>
<td>4.9 / –</td>
</tr>
<tr>
<td>10</td>
<td>f</td>
<td>54</td>
<td>MM</td>
<td>none</td>
<td>1× VelCD</td>
<td>1</td>
<td>4.0 / –</td>
</tr>
<tr>
<td>11</td>
<td>m</td>
<td>56</td>
<td>MM</td>
<td>none</td>
<td>4× VelCD</td>
<td>1</td>
<td>4.3 / –</td>
</tr>
<tr>
<td>12</td>
<td>m</td>
<td>61</td>
<td>NHL</td>
<td>none</td>
<td>6× R-CHOP</td>
<td>1</td>
<td>4.2 / –</td>
</tr>
<tr>
<td>13</td>
<td>f</td>
<td>60</td>
<td>NHL, CNS</td>
<td>none</td>
<td>4× MTX</td>
<td>1</td>
<td>4.8 / –</td>
</tr>
<tr>
<td>14</td>
<td>m</td>
<td>67</td>
<td>NHL</td>
<td>none</td>
<td>4× MTX</td>
<td>1</td>
<td>3.5 / –</td>
</tr>
</tbody>
</table>

m = male; f = female; MM = multiple myeloma; VelCD = Velcade, cyclophosphamide, dexamethasone; Cy = cyclophosphamide; R-CHOP = rituximab, doxorubicine, vincristine, prednisone; R-FC = rituximab, fludarabine, cyclophosphamide; R-DHAP = rituximab, dexamethasone, cytosine arabinoside, cisplatin; VM = Velcade, melphalan; VMP = Velcade, melphalan, prednisone; MTX = methotrexate; a = first apheresis after plerixafor application; b = summary of all aphereses with plerixafor application.

### Material and Methods

#### Patients

According to institutional policies, all patients were eligible for high-dose therapy and subsequent support with autologous HPC. In GI, 5 patients were treated during the compassionate use program after failure of a...
Mobilization and Apheresis

In GI, patients were mobilized with G-CSF 5 μg/kg bw subcutaneously twice daily and addition of plerixafor, 240 μg/kg bw subcutaneously 10 h before apheresis starting in the evening of the 4th day of G-CSF administration. G-CSF and plerixafor administrations were continued for a maximum of 3 apheresis days or until the minimum transplant dose of 2 × 10⁹ CD34+ cells/kg bw in patients with NHL, or if feasible 4 × 10⁹ CD34+ cells/kg bw in patients with MM was reached. In GI, mobilization regimens consisted of cyclophosphamide and G-CSF in MM patients, of ICE (ifosfamide, etoposide, and carboplatin) or of DexaBEAM (dexamethasone, BCNU, etoposide, cytosine arabinoside, and melphalan) in patients with NHL or of high-dose cytosine arabinoside and thiopeta in patients with primary CNS NHL. Apheresis were performed via a central venous line using a COBE Spectra® (CARIDIAN BCT, Heimstetten, Germany) cell separator with program version 6.1. Apheresis size, i.e., normal-volume apheresis or LVL according to earlier publications [19], was tailored according to patients' needs. The targeted minimum transplantation unit for autologous transplantation in patients with NHL was 2 × 10⁹ CD34+ cells/kg bw with an additional ‘back-up’ autograft and in patients with MM 4 × 10⁹ CD34+ cells/kg bw split in two bags, with an additional ‘back-up’ graft in both cases.

Laboratory Methods

Flow Cytometric Analysis

Immunophenotyping of CD34+ cells was performed using a commercially available kit (Stem Kit®, Beckman Coulter, Krefeld, Germany) as a single platform method according to the ISHAGE guidelines [24]. This kit consists of an anti-CD45-FITC monoclonal antibody (moAb), an anti-CD34-PE moAb, a respective isoclone control moAb, and the viability dye 7-AAD (7-aminoactinomycin A). These conjugated moAbs are already provided in defined combinations ready to use. Furthermore, stem count fluorospheres and ammonium chloride are provided with the kit.

All flow cytometric analyses were performed in duplicate, and the mean was calculated from the results of two analyses. Flow cytometric analyses were performed on an EPICS XL or a FC500 flow cytometer (Beckman Coulter).

CD34+ cells were analyzed in all patients of GI in PB starting on day 4 of G-CSF administration and on each day before apheresis. In GI patients, CD34+ cell monitoring in PB started on the day the leukocyte count reached 1×10⁶/l for the first time after chemotherapy-induced aplasia. Monitoring was continued each day until the last apheresis. In 6 of the 9 patients, CD34+ cell numbers were also evaluated in PB after the apheresis after addition of plerixafor.

Analysis of Clonogenic Growth

Clonogenic growth was analyzed using a commercially available kit (Stemcell Technologies Inc., Vancouver, BC, Canada). In brief, a satellite tube of the product was thawed at +37 °C and quickly diluted with cold phosphate-buffered saline (PBS); based on a previous flow cytometric analysis [25] of another tube of the same graft, 200 viable CD34+ cells were plated without washing steps in semisolid medium (Cellgrowth; Stemcell Technologies). The medium is supplemented with GM-CSF (granulocyte macrophage-colony stimulating factor), IL-3, and SCF (stem cell factor). Culture dishes were incubated at +37 °C, 5% CO₂ in a humidified atmosphere for 14 days. Cultures were analyzed for CFU-GM (colony forming units-granulocyte macrophage) growth with an inverted microscope (Invertoskop, Zeiss, Jena, Germany); based on the recommendations of the manufacturer, colonies containing at least 20 cells were counted as colonies.

Transplantation

Patients were transplanted after successful harvest of at least 2 × 10⁹ CD34+ cells/kg bw. For patients with MM, conditioning regimens consisted of melphalan in concentrations of 100, 120, 140 or 200 mg/m², depending on the patient’s age and condition. Patients with NHL were conditioned with Z-BEAM or R-BEAM (Y-90-Zevalin® 1,200 MBq, Rituximab® 375 mg/m², BCNU (carmustine) 300 mg/m², etoposide 4 × 200 mg/m², cytosine arabinoside 4 × 200 mg/m², and melphalan 100 or 140 mg/m²), and patients with primary NHL of the CNS were conditioned with Rituximab® 375 mg/m², BCNU 400 mg/m², and thiopeta 2 × 5 mg/kg bw.

Statistics

If not stated otherwise, data are given as median and range. The data of the different examinations were compared by the distribution-free Mann-Whitney if not stated otherwise using the Graph Pad PRISM program (San Diego, CA, USA), version 3.03. Results were considered statistically significant if the p value was < 0.05.

Results

Peak Counts of Leukocytes or CD34+ Cells before and after Apheresis

In GI, the median peak number of CD34+ cells in PB in a previous mobilization cycle consisting of chemotherapy and G-CSF was 6 cells/μl (range 2.5–14 cells/μl). On day 4 of the consecutive steady-state mobilization cycle with application of G-CSF in a daily subcutaneous dose of 10μg/kg bw, the median number of CD34+ cells was 5/μl (range 0–8/μl) in PB. These numbers increased significantly (p < 0.01) to a median number of 24 CD34+ cells/μl (range 18–37 CD34+ cells/μl). Interestingly, in patient #4, CD34+ cells were initially not detectable but increased after plerixafor administration to 18 cells/μl. Regarding leukocyte counts, an increase after plerixafor addition was detectable, but this was not significant. Patient #2 exhibited an extraordinary behavior of the leukocytes during G-CSF as well as plerixafor mobilization. On day 4 of G-CSF administration, he presented with an unexpectedly normal leukocyte count of 5,600/μl but detectable CD34+ cells of 6/μl. At the same time, the CD34 cell number increased to 8,500/μl but still remained in the normal range. Kinetics of leukocytes and of CD34+ cells are summarized in figure 1.

In GII, the median number of leukocytes increased significantly (p < 0.01) from 11,200/μl (range 2,900–19,800/μl) on the...
morning of the day of plerixafor addition to 28,300/µl (range 7,600–48,600/µl) in the morning after adding plerixafor. Additionally, by adding plerixafor the median number of CD34+ cells in PB increased significantly (p < 0.01) from a median number of 9 cells/µl (range 4–20/µl) to 50 cells/µl (range 22–112 cells/µl). In 6 of the patients, the enumeration of CD34+ cells/µl after the apheresis revealed a median of 26 cells/µl (range 17–45 cells/µl). Results are summarized in detail in figure 2. In addition, 4 of the patients in GII underwent a harvest in the morning of the day of plerixafor addition and had a median of 11 CD34+ cells/µl (range 9–11 CD34+ cells/µl).

Comparing the CD34+ cell numbers in PB between GI and GII, the median numbers of CD34+ cells were significantly (p = 0.019) higher in the chemomobilization group GII at both analyzed time points, i.e., in the morning before adding plerixafor in the evening as well in the morning after its addition (table 2).

Aphereses’ Characteristics

Comparing the processed number of total peripheral blood volumes (TPBV) during the apheresis on the first day after addition of plerixafor, in GI a median of 4.1 (range 2.9–5.6) and in GII a median of 4.3 (range 3.5–5.8) times the TPBV was processed. There was no difference between both groups. In GII, 4 patients underwent an apheresis before addition of plerixafor, and a median of 3.8 (range 3.3–4.1) times the TPBV was processed. After addition of plerixafor, all patients in GII were only harvested once. In GI, a median number of 3 (range 2–3) aphereses was performed. A Wilcoxon signed rank test comparing against a theoretical median of 1 displayed a significant (p = 0.03) difference.
these values with the values deduced from the up-mentioned simple calculation, the median recruited amount increased for the 6 analyzable patients from $3.33 \times 10^6$ CD34+ cells/kg bw (range $2.34–6.39 \times 10^6$ CD34+ cells/kg bw) to $5.54 \times 10^6$ CD34+ cells/kg bw (range $3.63–8.61 \times 10^6$ CD34+ cells/kg bw).

**Clonogenic Growth**

In all 14 patients, except for one of GII, clonogenic growth was analyzed in at least one product derived from aphereses after addition of plerixafor. CFU-GM assays were performed from 25 different products produced from 20 different aphereses of the 14 patients. In each assay colonies were detectable. A median number of 35 CFU-GM (range 12–54 CFU-GM) per 200 viable CD34+ cells were detected.

**Transplantation**

So far, all patients in GI and 8 of the 9 patients in GII were transplanted. Patients in GI received a median dose of...
3.03 × 10⁶ CD34+ cells/kg bw (range 2.52–3.32 × 10⁶ CD34+ cells/kg bw) and those in GII a median dose 3.69 × 10⁶ CD34+ cells/kg bw (range 2.33–7.06 × 10⁶ CD34+ cells/kg bw). All patients exhibited leukocyte and platelet engraftment after transplantation. In GI and GII, a leukocyte count above 1/l was reached after a median time of 10 days (range 8–11 days) and 11 days (range 8–12 days) after transplantation, respectively.

Discussion

In a substantial proportion of patients, transplantation of autologous HPC represents an accepted part of a multimodal treatment. A decisive prerequisite for planning, success, and assessing the risk profile of an autologous transplantation is the availability of a sufficient number of HPC, namely of CD34+ cells/kg bw. Therefore, mobilization and harvest of CD34+ cells need to be optimized with respect to the amount of collected cells as well as to the number of aphereses necessary to achieve high numbers of CD34+ cells. Several factors affecting the mobilization success have been identified, e.g., patient’s age, previous chemotherapy, and previous irradiation. Recently published randomized phase III studies [17, 18] showed that in NHL and MM patients the addition of a novel chemokine receptor antagonist, plerixafor (Mozobil) to a steady-state mobilization with G-CSF led to a significantly higher proportion of patients achieving the targeted transplantation dose of more than 5 and 6 × 10⁶ CD34+ cells/kg bw, respectively, in significantly less aphereses. Our findings in GI showed that patients mobilized subsequently with G-CSF alone after a previous unsuccessful chemo-mobilizing cycle present with less than 10 CD34+ cells/µl on day 4 of the steady-state mobilization. Three of the 5 patients even presented with CD34+ cell counts equal to or below 5 CD34+ cells/µl. In GI, all but one patient, who had 20 CD34+ cells/µl, had less than 20 cells/µl, and in 5 patients the CD34+ cell count was below 10/µl. According to recently published literature [14], patients with a peak count of less than 20 CD34+ cells/µl after chemotherapy and G-CSF mobilization were considered poor mobilizers. In addition, those with counts between 6 and 10/µl were regarded as relative and those with counts below 6/µl as absolute poor mobilizers. In our GI patients, the addition of plerixafor shifted all but 1 of the 5 patients to counts above 20 CD34+ cells/µl threshold. The one patient (#4) reaching 18 CD34+ cells/µl in PB the morning after addition of plerixafor had no detectable CD34+ cells before its addition. These data underline that low counts of CD34+ cells or even non-detectable CD34+ cells in PB before potential addition of plerixafor are not predictive for its effect. Additionally, an unexpectedly low or no increase of the leukocyte count after 4 days of G-CSF mobilization seems to be negligible. In GII, all 9 patients exhibited a CD34+ cell count equal or below 20 cells/µl, and 5 patients even had counts below 10 CD34+ cells/µl. After administration of plerixafor, the number of CD34+ cells/µl increased above 20 CD34+ cells/µl for all 9 patients.

In GI, all patients achieved the goal of one transplantation dose of at least 2 × 10⁶ CD34+ cells/kg bw. In this group more than one transplantation dose of 2 × 10⁶ CD34+ cells/kg bw could be harvested in 4 patients after repeated administrations of plerixafor and 2–3 LVL. In GII, all patients achieved the minimum transplantation dose of east 2 × 10⁶ CD34+ cells/kg bw already after the first dose of plerixafor and one LVL, and 6 of the 9 patients (66%) achieved the optimal dose of more than 4–5 × 10⁶ CD34+ cells/kg bw by this approach.

Our data show as already published in a different study some years ago [19] that the yield in the aphereses was in both groups higher than the number of CD34+ cells circulating in the PB before apheresis. Interestingly, the intra-apheresis recruitment was highest in the patients of GI after addition of plerixafor compared with the patients from GI when normalized by one processed TPBV. Furthermore, the recruitment was smallest in the 4 aphereses performed in patients of GII before application of plerixafor. In addition, the recruitment calculated for 6 of the GII patients with considering postapheresis CD34+ cell counts even revealed a substantially higher recruitment compared to the formerly published data [26]. Possible explanations for the different extent of recruitment between GI and GII might be the different pre-apheresis CD34+ cell counts in PB or the difference in mobilization scheme, i.e., mobilization with chemotherapy and G-CSF or mobilization with G-CSF alone. The difference in recruitment in GII patients before and after addition of plerixafor might be due to the very low numbers of CD34+ cells before. Additionally a possible alternative explanation might be the addition of plerixafor itself which might be as well the explanation for the difference to earlier published data.

Finally, the addition of plerixafor increased the numbers of CD34+ cells in all but 1 patient so that the patients were no longer considered poor mobilizers. Nevertheless, especially in GI patients only the combination with LVL enabled the harvest of sufficient numbers of HPC for one or two transplantations. Apart from this, the scheduling of aphereses in poor or non-optimally mobilizing patients could become more easy and calculable by the addition of plerixafor. Regarding the intra-apheresis recruitment, further studies should be performed to elucidate the extent of potential influence of plerixafor and the apheresis’ size on it.

Disclosure Statement

A.H. received remunerations from the company GENZYME / SA-NOFI-AVENTIS for talks and for participation in advisory boards.
References


